You are Unregistered, please register to gain Full access.
Welcome to the xenoMED, an online Medical Community where Academically sound, Professionally conscious and Socially responsible Medical Students, Doctors & Health Professionals interact with each other globally.
Medicine is the only profession that incessantly tries to destroy its own existence. Howsoever you may be associated with basic and/or clinical medicine - student or professor, physician or surgeon, undergraduate or postgraduate - this is your place to share your knowledge, and learn more. Just get the message across!
You are currently viewing our communiy as a guest which gives you limited access to view most discussions and access our other features. By joining our free community you will have access to post topics, communicate privately with other members (PM), respond to polls, upload content and access many other special features. Registration is fast, simple and absolutely free so please, Join Our Medical Cummunity Today!
If you have any problems with the registration process or your account login, please contact us.
Archemix Announces Initiation Of Phase I Clinical Trial For Novel, Selective Anti-Pla -
04-01-2007, 12:20 AM
Archemix Corp. announced the successful initial dosing with ARC1779 in its first-in-human Phase I study.ARC1779 represents a novel therapeutic principle the reduction of platelet aggregation and thrombosis by inhibition of von Willebrand Factor (vWF). [click link for full article]
Angel xenoMED | NDR “Nothing brings me more happiness than helping people in the society. It is a goal and an essential part of my life - a kind of destiny.”
Linear Mode
